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Expert panel consensus statement on the optimal use of
pomalidomide in relapsed and refractory multiple myeloma
MA Dimopoulos1, X Leleu2, A Palumbo3, P Moreau4, M Delforge5, M Cavo6, H Ludwig7, GJ Morgan8, FE Davies8, P Sonneveld9,
SA Schey10, S Zweegman11, M Hansson12, K Weisel13, MV Mateos14, T Facon2 and JFS Miguel15
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory
multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is
a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and
bortezomib. The optimal starting dose of pomalidomide is 4mg given on days 1–21 of each 28-day cycle, whereas dexamethasone
is administered at a dose of 40mg weekly (reduced to 20mg for patients aged 475 years). The treatment should continue until
evidence of disease progression or unacceptable toxicity. Dose-modiﬁcation schemes have been established for patients who
develop neutropenia, thrombocytopaenia and other grade 3–4 adverse events during pomalidomide therapy. Guidance on the
prevention and management of infections and venous thromboembolism is provided, based on the available clinical evidence
and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age,
renal impairment or unfavourable cytogenetic features, is also discussed.
Leukemia (2014) 28, 1573–1585; doi:10.1038/leu.2014.60
INTRODUCTION
Despite recent treatment advances, multiple myeloma (MM)
remains an incurable disease in the majority of patients.
The management of patients who have already received multiple
prior therapies poses a distinct clinical challenge.1 Because
of the advanced nature of the disease, these patients often have
signiﬁcant disease-related comorbidity, such as thrombo-
cytopaenia, bone disease or renal impairment,2,3 as well as
indications of marked immunosuppression.2,4–8 Patients may have
poor quality of life9 because of disease-related symptoms, adverse
events from prior therapies or cumulative toxicity, such as
impaired bone marrow reserve2 or neuropathy.10 Periods of
remission become increasingly shorter with each subsequent
therapy,11 and the prognosis for patients who have exhausted
treatment with immunomodulatory drugs (thalidomide or
lenalidomide) and bortezomib is poor: the expected median
event-free survival is 5 months and median overall survival (OS) is
9 months.1 Thus, there is an unmet need for effective and well-
tolerated novel antimyeloma therapies that improve outcomes in
patients with advanced myeloma.
Pomalidomide (Imnovid, Celgene Europe Ltd, Uxbridge, UK;
Pomalyst, Celgene Corporation, Summit, NJ, USA) is an IMiDs(R)
immunomodulatory compound that has demonstrated activity in
MM patients with disease refractory to lenalidomide and
bortezomib.12–16 Pomalidomide was approved by the FDA (Food
and Drug Administration) in February 2013 and the EMA
(European Medicines Agency) in August 2013 for use alone (in
the United States) or in combination with dexamethasone in
patients with MM who have received at least two prior therapies
including lenalidomide and bortezomib and have demonstrated
disease progression on their last therapy17 (within 60 days of the
last treatment for the United States).18 The aim of this review is to
provide practical guidance to help haematologists and oncologists
maximise efﬁcacy and minimise safety risks through appropriate
dosing, monitoring and intervention for adverse events with
pomalidomide treatment.
POMALIDOMIDE
Mechanism of action
Pomalidomide is a distinct IMiDs(R) immunomodulatory com-
pound with multiple cellular effects that inhibit the growth of
myeloma cells.19 Pomalidomide has direct effects on myeloma
cells by inhibiting their growth and survival,20–30 and it also
inhibits stromal support from the bone marrow microenvironment
that can promote myeloma cell growth.2,31–39 In addition,
pomalidomide has potent immunomodulatory effects that
enhance the immune response to myeloma cells by stimulating
natural killer cells40–42 and by inhibiting regulatory T cells.43
Recent evidence suggests that the effects of pomalidomide may
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be partially mediated by cereblon, a component of the E3
ubiquitin ligase complex.44–46 Preclinical data indicate that
pomalidomide is active in drug-resistant myeloma cell lines,44,47
including lenalidomide-resistant cells,48,49 and produces syner-
gistic effects when combined with dexamethasone.50
Efﬁcacy in clinical trials
In a phase I/II study (MM-002), the combination of pomalidomide
and low-dose dexamethasone was assessed in patients with
relapsed and refractory multiple myeloma (RRMM) who had
received prior lenalidomide and bortezomib.14,51 The median
number of prior therapies was 5 (range 1–13); all patients had
received prior steroids, lenalidomide and bortezomib, and 62%
were refractory to both lenalidomide and bortezomib.14 In phase I
of the study, the dose-limiting toxicity (grade 4 neutropenia)
occurred at a pomalidomide dose of 5mg; the maximum tolerated
dose of pomalidomide was, therefore, 4mg given on days 1–21 of
each 28-day cycle in combination with low-dose dexamethasone
(40mg weekly for patients p75 years; 20mg weekly for patients
475 years).51 With this dose and schedule and in the pivotal
phase II trial, pomalidomide plus low-dose dexamethasone was
associated with an overall response rate of 33% and median
duration of response of 8.3 months. With a median follow-up
of 14.2 months, the median progression-free survival (PFS) and
OS were 4.2 and 16.5 months, respectively.14 In comparison,
response to single-agent pomalidomide was 18% with a median
duration of response, PFS and OS of 10.7, 2.7 and 13.6 months,
respectively, indicating that the addition of low-dose dexametha-
sone to pomalidomide improves efﬁcacy.14 Subanalyses indicated
that the efﬁcacy of pomalidomide plus low-dose dexamethasone
was similar regardless of whether the patient was refractory to
lenalidomide or bortezomib as last prior therapy.52
In a randomised phase II trial (IFM 2009-02), two different
schedules of pomalidomide administration were compared
in combination with low-dose dexamethasone (40mg weekly) in
patients who were refractory to, or had never achieved a
response to, lenalidomide and bortezomib.15 Patients received
pomalidomide (4mg) for either 21 days or 28 days of each
28-day cycle, plus dexamethasone, using a similar schedule as in
the MM-002 trial. The schedule of administration did not affect
the overall response rate (35% vs 34%) or time to progression
(TTP; 5.4 months overall), and the median PFS and OS for the total
study population were 4.6 and 14.9 months, respectively.
The investigators concluded that the 21/28-day schedule is
preferred because it provided equivalent efﬁcacy while
facilitating long-term management by requiring less growth-
factor support compared with the 28/28-day schedule (median
number of treatment cycles: 8 vs 6). Notably, the TTP achieved
with pomalidomide plus low-dose dexamethasone in responding
patients was better than that achieved with the last prior therapy
before entering the study,15 suggesting that pomalidomide may
have the potential to change the natural course of the disease
(characterised by progressively shorter remissions with each
subsequent treatment).11
In a randomised and pivotal phase III trial (MM-003), pomali-
domide plus low-dose dexamethasone was compared with high-
dose dexamethasone in patients who had failed both bortezomib
and lenalidomide treatment.16 With a median follow-up of 10
months, pomalidomide plus low-dose dexamethasone decreased
the rate of progression by 52% (PFS 4.0 vs 1.9 months; hazard ratio
(HR)¼ 0.48; 95% conﬁdence interval (CI) 0.39–0.60; Po0.001) and
signiﬁcantly improved OS (12.7 vs 8.1 months; HR¼ 0.74; 95% CI
0.56–0.97; P¼ 0.03). However, the impact on OS is probably
underestimated because of the confounding effect of crossover
that occurred in the high-dose dexamethasone arm. At the
time of the analysis, 50% of patients assigned to high-dose
dexamethasone had received pomalidomide, and by month 16 of
study treatment, it was estimated that all patients assigned to
high-dose dexamethasone would have received pomalidomide as
salvage therapy, underscoring the superiority of the combination
regimen.16 Similar efﬁcacy was seen for pomalidomide plus low-
dose dexamethasone vs high-dose dexamethasone in patients
with disease refractory to both lenalidomide and bortezomib (PFS
3.7 vs 2.0 months; HR¼ 0.52; Po0.001 and OS 11.1 vs 7.7 months;
HR¼ 0.77; P¼ 0.096) and in those who received lenalidomide as
last prior therapy (PFS 4.6 vs 1.9 months; HR¼ 0.38; Po0.001 and
OS 12.3 vs 7.3 months; HR¼ 0.53; P¼ 0.01).16
Data from these large multicentre trials support the use of
pomalidomide plus low-dose dexamethasone in patients with
RRMM who have received prior lenalidomide and bortezomib.
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Figure 1. Treatment algorithm for patients who have failed prior therapy for RRMM. BORT, bortezomib; LEN, lenalidomide; POM/LoDEX,
pomalidomide plus low-dose dexamethasone.
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Practical issues regarding the optimal use of pomalidomide in this
setting are discussed below.
CANDIDATES FOR POMALIDOMIDE PLUS LOW-DOSE
DEXAMETHASONE THERAPY
Determining whether a patient is eligible for treatment with
pomalidomide plus low-dose dexamethasone requires careful
consideration of multiple factors, particularly the type of prior
therapy, the quality of response and the tolerability of the
prior therapy (Figure 1).53 In general, for patients who respond to
prior therapy, tolerate it well and have a period of unmaintained
remission not inferior to the median TTP or PFS expected with
prior therapy, retreatment may be considered. For patients
who have a poor response to prior therapy or do not tolerate it
well, switching to an alternative novel agent is recommended.53
For patients who have exhausted novel therapies (lenalidomide
and bortezomib), treatment options include pomalidomide plus
low-dose dexamethasone or enrolment in a clinical trial or
palliative care.53 The proteasome inhibitor carﬁlzomib is
approved in the United States but not currently approved for
use in the European Union.
Candidates for pomalidomide plus low-dose dexamethasone
therapy must have received at least two prior therapies and have
documented disease progression on their last therapy.17 In the
MM-003 trial, the proportion of patients treated with
pomalidomide plus low-dose dexamethasone who had disease
refractory to lenalidomide, bortezomib or both was 95%, 79% and
75%, respectively,16 per available hospital records of prior
treatment. The trial also stratiﬁed the patients based on patient-
reported data at study entry. Most patients (82%) were classiﬁed
as having disease refractory to lenalidomide and bortezomib,
whereas smaller proportions of patients were intolerant to
bortezomib (15%) or had relapsed on lenalidomide and/or
bortezomib and were refractory to any subsequent therapy
(3%). In the clinical setting, appropriate candidates for
pomalidomide therapy are, therefore: patients who have
received prior lenalidomide and bortezomib and have become
refractory to these agents; patients who have relapsed on
lenalidomide and/or bortezomib and are refractory to their
subsequent therapy; and patients unresponsive or intolerant to
existing agents.
OPTIMAL DOSE AND SCHEDULE
Optimal pomalidomide dose and schedule
Based on the available clinical evidence, the recommended
starting dose of pomalidomide is 4mg given on days 1–21 of
each 28-day cycle until disease progression.17 This dose was used
in the MM-002 trial,14,51 MM-003 trial16 and IFM 2009-02 trial15 and
represents the most robust data on pomalidomide currently
available in RRMM. Early studies explored various doses and
schedules of pomalidomide.54,55 This led to a series of cohort
studies conducted by the Mayo Clinic (Rochester, MN, USA) using
pomalidomide doses of 2 or 4mg given either continuously or for
21 days of each 28-day cycle;12,13,56,57 however, these were not
dose-ﬁnding studies. In the phase I dose-escalation portion of the
MM-002 trial, response and duration of response tended to
increase with increasing doses of pomalidomide, and the
maximum tolerated dose was determined to be 4mg when
given for 21 days of each 28-day cycle.51 In the IFM 2009-02 trial,
pomalidomide 4mg with a less intensive 21/28-day schedule,
rather than continuous dosing, was recommended for further
investigation, because the 1-week treatment break allowed for
bone marrow recovery, leading to improved tolerability.15
Based on clinical trial experience, RRMM patients should have
adequate blood cell counts, including absolute neutrophil count
X1000/ml before starting pomalidomide plus low-dose
dexamethasone.16 Platelet count should be X75 000/ml if
o50% of bone marrow nucleated cells are plasma cells or
X30 000/ml if X50% of bone marrow nucleated cells are
plasma cells.16 For patients with absolute neutrophil count and
blood cell counts below these thresholds, pomalidomide
plus low-dose dexamethasone may be considered with the
provision of adequate growth factor support and platelet
transfusion.
Expert panel opinion
 The optimal starting dose for pomalidomide is 4mg daily, given orally
 The optimal schedule is 21 days of each 28-day cycle
Optimal dexamethasone dose and schedule
High-dose dexamethasone (40mg daily on days 1–4, 9–12 and
17–20 of each 28-day cycle) is often used as rescue therapy in
heavily pretreated patients with RRMM, and has been used as a
comparator in registrational studies of novel therapies, including
lenalidomide58,59 and bortezomib.60 However, evidence suggests
that low-dose dexamethasone (40mg weekly) may be more
effective and better tolerated than high-dose dexamethasone
when combined with lenalidomide in newly diagnosed patients.61
The three main trials of pomalidomide in RRMM (MM-002, MM-003
and IFM 2009-02) therefore evaluated low-dose dexamethasone in
combination with pomalidomide. Notably, in all three trials, the
dose of dexamethasone was reduced to 20mg weekly in patients
aged 475 years to improve the tolerability of the regimen for
these patients, particularly with regard to the risk of infection. In
clinical practice, patients’ vulnerabilities, comorbidities and age,
both biological and chronological, should also be examined
before initiating dexamethasone.62 Some experts recommend a
lower age threshold of 70 years.
Expert panel opinion
 When used in combination with pomalidomide, current evidence
suggests that dexamethasone should be given at a dose of 40mg
weekly for patients aged p75 years and 20mg weekly for patients
aged475 years. The age threshold can be lower in some patients at
the discretion of the treating physician, considering patient comor-
bidities and disabilities
Optimal duration of therapy
In clinical trials, pomalidomide plus low-dose dexamethasone
therapy was given until evidence of disease progression or
unacceptable toxicity, and it is recommended to continue
pomalidomide plus low-dose dexamethasone treatment until
disease progression.17 In the IFM 2009-02 trial, 10 of 85 patients
(12%) received therapy for more than 30 months, supporting the
long-term safety of pomalidomide-based therapy.63 Currently,
there is no evidence to support stopping or reducing the dose of
pomalidomide in responding patients. However, it is the opinion
of the panel members that reducing the dose of dexamethasone
may be considered to improve long-term tolerability, based on
the known safety proﬁle of dexamethasone and experience with
lenalidomide and dexamethasone.61 An ongoing Australian
randomised trial evaluating four courses of pomalidomide plus
dexamethasone followed by either pomalidomide monotherapy
or pomalidomide plus dexamethasone will provide useful
information on the duration of dexamethasone therapy in
nonprogressing patients.64
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Expert panel opinion
 Continuous treatment with pomalidomide plus low-dose dexametha-
sone at the best tolerated doses is recommended until there is
evidence of disease progression or unacceptable toxicity
 Continue treatment in patients without disease progression; once a
response plateau has been reached, consider reducing the dose of
dexamethasone to improve the long-term tolerability of treatment
with pomalidomide plus low-dose dexamethasone
MANAGING ADVERSE EVENTS
The types of adverse events seen with pomalidomide are similar
to those seen with lenalidomide. The most common grade 3–4
adverse event associated with pomalidomide plus low-dose
dexamethasone is myelosuppression. In clinical trials, the
incidence of grade 3–4 neutropenia, thrombocytopaenia and
anaemia ranged from 41 to 62%, from 19 to 27% and from 22 to
36%, respectively.15,16,65 Neutropenia and other adverse events of
clinical interest, as well as recommended dose adjustments for
pomalidomide, are discussed below.
Neutropenia
Based on clinical experience with lenalidomide,58,59 neutropenia
was anticipated to be a primary adverse event of pomalidomide
therapy. Indeed, neutropenia is one of the most common adverse
events observed in patients treated with pomalidomide plus
low-dose dexamethasone.15,16,65 The reported incidence of grade
3–4 neutropenia with pomalidomide plus low-dose dexametha-
sone ranges from 41 to 62%.15,16,65 In MM-003, 26% of patients
developed grade 3 neutropenia and 22% had grade 4
neutropenia,16 with most cases occurring within the ﬁrst few
cycles of therapy.66 Few patients (o10%) experienced febrile
neutropenia.16,65
Depending on its severity, neutropenia may be managed with
dose interruptions, dose modiﬁcations and/or growth factor
support. In MM-002, 46% of all patients treated with pomalido-
mide plus low-dose dexamethasone received growth factor
support; most cases of neutropenia resolved (49 of 55 patients
with any grade neutropenia (89%)) in the pomalidomide plus
low-dose dexamethasone group after a median of 1.4 months.65 In
MM-003, the median time to onset of neutropenia was 0.7 months
(range 0.03–8.7 months).66 Growth factor support was used in 43%
of patients treated with pomalidomide plus low-dose
dexamethasone,16 whereas 23% of patients required pomali-
domide dose interruption because of neutropenia, and only 8%
required a reduction in pomalidomide dose.66
Given the inherent risk of infection in patients with RRMM,4,67
those treated with pomalidomide should be monitored closely for
neutropenia and other haematological adverse events. Unlike the
long-lasting neutropenia associated with cytotoxic chemotherapy,
the neutropenia with pomalidomide is usually short-lived.
Recommended dose modiﬁcations for pomalidomide-related
neutropenia and thrombocytopaenia have been established
(Figures 2 and 3, respectively). Growth factors may be considered
for patients who develop neutropenia during pomalidomide
therapy.17 There is limited evidence available regarding prophyl-
actic use of growth factors in patients receiving pomalidomide.
For lenalidomide, some evidence suggests that prophylactic use of
granulocyte colony-stimulating factor (300 mg/kg for 3 days (days
22–24 of each 28-day cycle)) during the ﬁrst few treatment cycles
may reduce the risk of further neutropenia, treatment delays, dose
modiﬁcations and infection.68,69 Guidelines have been developed
on the use of growth factor support in cancer patients in
general70–73 and for RRMM patients receiving lenalidomide
therapy.69 Based on the above data, prophylactic granulocyte
colony-stimulating factor administration (that is, twice a week)
could be considered in patients with baseline extensive bone
marrow involvement and/or low neutrophil count.
Expert panel opinion
 Perform a complete blood count at baseline, every 1–2 weeks
(depending on the condition of the patient) for the ﬁrst 8 weeks of
therapy, and monthly thereafter
 Follow the recommended dose-modiﬁcation scheme for pomalido-
mide-related neutropenia and thrombocytopaenia (Figures 2 and 3,
respectively)
 Prophylactic use of granulocyte colony-stimulating factor at the
physician’s discretion during the ﬁrst few treatment cycles may reduce
the risk of neutropenia
 Consider growth factor use for cases of neutropenia with the goal of
maintaining patients on therapy
Infection
Increased susceptibility to bacterial infection is one of the most
common clinical problems in patients with myeloma: 475% of
patients will develop a serious infection at some time in the course
of the disease.74 The most common types of infection are
respiratory and urinary tract infections; the most frequently
encountered pathogens are Streptococcus pneumoniae,
Haemophilus inﬂuenza, Staphylococcus aureus and Klebsiella
pneumoniae in the lungs and Escherichia coli and other Gram-
negative bacteria in the urinary tract.74 Various factors contribute
to the increased risk of infection. Disease-related factors include
B-cell dysfunction (manifested as hypogammaglobulinaemia), low
CD4þ cell count and natural killer cell dysfunction, all of which
contribute to immunodeﬁciency that is often present even in
untreated myeloma patients.4,67 The advanced age of most
myeloma patients (the median age at diagnosis is B70 years75)
is associated with reduced physiological reserve of various organ
systems and several physical, cognitive and social conditions that
can predispose patients to opportunistic infections.67 Lastly,
patients with RRMM may develop cumulative immunodeﬁciency
after exposure to multiple therapies that increase infection risk.67
Infection is a commonly reported adverse event in trials of
pomalidomide. In IFM 2009-02, 23% of patients had grade 3–4
infection (19% with the 21/28-day schedule and 27% with 28/28-
day schedule).15 In MM-003, grade 3–4 infection occurred in 30%
and 24% of patients treated with pomalidomide plus low-dose
dexamethasone and high-dose dexamethasone, respectively.16
The reported incidence of grade 3–4 pneumonia ranged from 13
to 22%.15,16,51,65 Notably, the occurrence of neutropenia in MM-
003 did not appear to affect the incidence of infection, and most
infections occurred in the absence of neutropenia (66% with
pomalidomide plus low-dose dexamethasone vs 86% with high-
dose dexamethasone); few patients (2%) discontinued treatment
because of infection.16
Given the increased risk of infection, routine vaccinations are
recommended for the patients and their contacts, and antibiotic
prophylaxis should be considered for all patients receiving
pomalidomide.53,71 Prophylaxis should be given for a minimum
of the ﬁrst 3 months of therapy, when the risk of infection is the
highest.53,69 For patients at high risk of infection, such as those
with low blood counts or a previous history of infection or both,
antibiotic prophylaxis is recommended for the complete duration
of pomalidomide plus dexamethasone therapy. An optimal
antibiotic prophylaxis regimen has not been determined, but
several options are available (trimethoprim–sulfamethoxazole,
quinolones, penicillin, amoxicillin and so on); clinicians should
follow standard protocols as established by their institution.53,71
Caution is warranted when using the quinolones ciproﬂoxacin and
enoxacin because they strongly inhibit the activity of CYP1A2, the
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cytochrome P450 isoform primarily responsible for the
metabolism of pomalidomide (Table 1) and can therefore increase
exposure to pomalidomide.76 If these quinolones are administered
concurrently with pomalidomide, patients should be monitored
closely for adverse events. Importantly, the quinolones
norﬂoxacin, oﬂoxacin, levoﬂoxacin, moxiﬂoxacin and
gemiﬂoxacin have little or no effect on CYP1A2 (refs. 77,78) and
are therefore not expected to affect pomalidomide metabolism;
these agents are preferred when quinolones must be
administered concurrently with pomalidomide.
For patients who develop infection during pomalidomide
therapy, treatment should be interrupted (regardless of the
presence or absence of neutropenia) until the infection resolves
and then may be restarted. Treatment of infection in patients
receiving pomalidomide should follow standard protocols and
include immediate empirical antibiotic treatment that may be
adapted as needed, when results from blood cultures and other
tests become available.53,71
Expert panel opinion
 Antibiotic prophylaxis should be considered for the ﬁrst three cycles
of pomalidomide therapy for all patients, because of the high risk of
infection in this period
(Continued )
Expert panel opinion
 For patients with a very high risk of infection (low blood counts, prior
history of infection or both), consider antibiotic prophylaxis for the
duration of pomalidomide therapy
 Caution is warranted when pomalidomide is administered concur-
rently with strong inhibitors of CYP1A2, such as ciproﬂoxacin and
enoxacin, as these agents may increase exposure to pomalidomide
and therefore increase the risk of adverse events
 Early intervention is warranted for patients who develop infection,
including treatment interruption and immediate initiation of empirical
antibiotic treatment
Venous thromboembolism (VTE)
VTE, including deep vein thrombosis and pulmonary embolism, is
a rare but potentially serious adverse event that has been
reported with immunomodulatory drug therapy.58,59,79,80 In both
MM-002 and MM-003, the reported incidence of deep vein
thrombosis in patients treated with pomalidomide plus low-dose
dexamethasone was 2%, although thromboprophylaxis was
given,14,16 and, in IFM 2009-02, the incidence was 4% among
those who received aspirin prophylaxis.15 The incidence of deep
Yes No
For each subsequent drop <0.5x109/l
ANC ≥1x109/l?
ANC ≥1x109/l? ANC ≥1x109/l?
Yes No
Resume pomalidomide 
at 3 mg daily
Pomalidomide
at 4 mg daily
Interrupt pomalidomide treatment
and add G-CSFb
Resume pomalidomide at 1 mg less
than the previous dose 
Interrupt pomalidomide treatment,
add G-CSFb and follow CBC weekly
Add G-CSFb for 1 cycle and
 follow CBC weekly
Continue pomalidomide
at 4 mg daily 
ANC <0.5x109/l?
Febrile neutropenia?a
Start pomalidomide 4 mg daily
Figure 2. Recommended pomalidomide dose modifications for neutropenia.17 The minimum blood levels required to start treatment with
pomalidomide at the full dose of dose 4mg are ANC X1 109/l; platelets X75/109/l or X30 if X50% of bone marrow nucleated cells are
plasma cells. It is not recommended to give pomalidomide in doses o1mg. ANC, absolute neutrophil count; CBC, complete blood count;
G-CSF, granulocyte colony-stimulating factor. aFebrile neutropenia is defined as fever X38.5 1C and ANC o1 109/l. bG-CSF cycle; 300 mg/kg
for 3 days (days 22–24 of each 28-day cycle).
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vein thrombosis in patients treated with pomalidomide appears to
be lower than that reported historically for lenalidomide,58,59
although this may reﬂect increased thromboprophylaxis use that
was mandatory in trials of pomalidomide.
All patients with MM treated with immunomodulatory drugs,
including pomalidomide, should receive thromboprophylaxis. The
optimal approach to thromboprophylaxis has not been estab-
lished, but it is generally agreed that the type of thrombopro-
phylaxis selected depends on the risk of VTE, as determined by the
individual patient’s characteristics and the proposed treatment
regimen.79–81 Aspirin prophylaxis is generally recommended for
patients with standard risk of VTE, and low-molecular-weight
heparin (prophylactic dose) or vitamin K antagonists (international
normalised ratio 2–3) are recommended for patients with high risk
of VTE (Figure 4). Several risk factors for VTE have been identiﬁed
for patients with cancer82 and for MM speciﬁcally.81 Possible
risk factors include treatment-related factors (high-dose
dexamethasone, doxorubicin, multi-agent chemotherapy, IMiDs
Table 1. Pharmacokinetic properties of lenalidomide and pomalidomide17,88
Pharmacokinetic property Lenalidomide Pomalidomide
Absorption (time to Cmax, h) 0.5–2 2–3
Elimination (median plasma half-life, h)
Healthy volunteers B3 B9.5
Myeloma patients B3–5 B7.5
Excretion (% excreted unchanged in urine) 82 2
Key drug–drug interactions
P-gp substrate Yes; monitor closely if co-administered
with P-gp inhibitorsa
Yes; but no clinically relevant effect seen when
co-administered with the P-gp inhibitor ketoconazole
CYP inhibitor/inducer No; unlikely to affect exposure
of other drugs
No; unlikely to affect exposure of other drugs
CYP substrate No Yes; monitor closely if co-administered with
strong CYP1A2 inhibitorsb
Abbreviations: CYP, cytochrome P450; P-gp, P-glycoprotein. aCommon P-gp inhibitors include cyclosporine, clarithromycin, itraconazole, ketoconazole,
quinidine and verapamil. bCommon strong inhibitors of CYP1A2 include ciprofloxacin, enoxacin and fluvoxamine.
Yes No
Platelet count ≥50x109/l?
For each subsequent drop <25x109/l
Platelet count ≥50x109/l?
Resume pomalidomide at 3 mg daily
Interrupt pomalidomide treatment
Resume pomalidomide at 1 mg less
than the previous dose
Interrupt pomalidomide treatment 
and follow CBC weeklya
Continue pomalidomide 
at same dose level
Platelet count <25x109/l?
Start pomalidomide 4 mg daily
Figure 3. Recommended pomalidomide dose modifications for thrombocytopaenia.17 The minimum blood levels required to start treatment
with pomalidomide at the full dose of dose 4mg are ANCX1 109/l; plateletsX75/109/l orX30 ifX50% of bone marrow nucleated cells are
plasma cells. It is not recommended to give pomalidomide in doses o1mg. CBC, complete blood count. aConsider frequent platelet
transfusions.
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immunomodulatory compounds, erythropoietin) and patient-
related factors (obesity, prior VTE, central venous catheter or
pacemaker, infection, immobilisation, surgery, trauma, organ
dysfunction, blood-clotting disorders).82,83 In a large multicentre
observational study (MELISSE), factors that predicted VTE in MM
patients treated with immunomodulatory drugs (thalidomide or
lenalidomide) include shorter time from diagnosis and
concomitant use of erythropoietin.79 Evidence also suggested
that development of deep vein thrombosis was unlikely to
negatively affect survival outcomes.79 In 200 consecutive MM
patients treated with lenalidomide at a single institution, the
incidence of VTE was higher in previously untreated patients than
in RRMM patients (9.4% vs 4.5%); among RRMM patients, the
incidence of VTE was increased in patients aged 465 years
compared with younger patients (8.1% vs 1.6%), despite increased
use of low-molecular-weight heparin or vitamin K antagonists in
older patients.84 In the 108 patients who received aspirin
prophylaxis, a single-nucleotide polymorphism in the NFkB1
gene was identiﬁed that was associated with increased risk of
VTE.84 From a practical point of view, in patients treated with
pomalidomide and low-dose dexamethasone, the main high-risk
features for VTE are: a history of prior VTE, immobilisation and
concomitant use of an erythropoiesis-stimulating agent. For
patients who develop VTE during pomalidomide-based therapy,
treatment should be interrupted temporarily and anticoagulation
therapy should be initiated.65 Treatment may be resumed,
probably within a few weeks, although the optimal timing has
not been determined.
Expert panel opinion
 Follow existing guidelines on thromboprophylaxis during immuno-
modulatory drug therapy (Figure 4), that is, aspirin prophylaxis for
patients with standard risk and low-molecular-weight heparin for
patients with at least one risk factor, to reduce the incidence of VTE to
o5%
 Patients at high risk for VTE because of concomitant medical
condition should continue to receive anticoagulation as prescribed
 For patients with high risk because of reasons other than comorbidity,
VTE risk can be reassessed after 4 months, and those with standard
risk can switch to aspirin
Peripheral neuropathy
Peripheral neuropathy is a common and potentially treatment-
limiting adverse event associated with thalidomide and bortezo-
mib, but lenalidomide does not appear to cause substantial
neurotoxicity.85 Although patients with grade X2 peripheral
neuropathy were excluded from pomalidomide trials, the
incidence of newly occurring or worsening peripheral neuro-
pathy during pomalidomide treatment was low. In MM-002,
no cases of grade 3–4 peripheral neuropathy were observed
despite the fact that 73% of patients in the pomalidomide
plus low-dose dexamethasone arm had a history of peripheral
neuropathy.65 In MM-003, 15% of patients treated with
pomalidomide plus low-dose dexamethasone developed any-
grade treatment-emergent peripheral neuropathy; 52% of these
cases had grade 1 peripheral neuropathy at baseline.66 The
incidence of grade 3–4 peripheral neuropathy was p2% in both
treatment arms.16
For patients who develop grade 3 peripheral neuropathy,
pomalidomide treatment should be interrupted, but may be
resumed at a lower dose if the neuropathy resolves to grade 0–1;
pomalidomide should be discontinued in patients who develop
grade 4 peripheral neuropathy (Figure 5).65,66
Expert panel opinion
 There are no concerns related to peripheral neuropathy for pomalido-
mide treatment
Other adverse events
Other clinically relevant nonhaematological adverse events
observed with pomalidomide plus low-dose dexamethasone
include fatigue, gastrointestinal disorders, muscle cramps and
rash. In MM-003, fatigue was reported in 34% of patients, although
only 5% had grade 3 fatigue and no cases of grade 4 fatigue were
observed.16 Any-grade diarrhoea, constipation and nausea
occurred in 22%, 22% and 15% of patients, respectively, but
grade 3 events were uncommon (1%, 2% and 1%, respectively).
Muscle cramps and rash, which occurred in 16% and o10% of
patients treated with pomalidomide plus low-dose
dexamethasone, respectively, appear to be less common with
pomalidomide than with lenalidomide.58,59 Acute pulmonary
toxicity is a rare, but serious, adverse event that manifests itself
as acute interstitial pneumonitis. This complication needs to be
recognised and treated promptly with corticosteroids.86
In most cases, nonhaematological grade 1–2 adverse events can
be managed with standard interventions; patients with grade 3–4
adverse events may require pomalidomide dose modiﬁcations or
discontinuation, as described in Figure 5. Anecdotally, calcium and
magnesium supplementation or quinine may ameliorate muscle
cramps. Caution is warranted when using pomalidomide in
patients who developed rash during prior treatment with
thalidomide or lenalidomide. For patients with mild-to-moderate
maculopapular eruption or erythema, treatment with low-dose
prednisone and antihistamines may be considered; for those with
symptomatic and generalised rash, pomalidomide dose delay or
reduction should be considered. Pomalidomide should be
Standard risk (no risk factors)? High risk?
Aspirin prophylaxis, continuously for
the duration of POM/LoDEX therapy
LMWH for a  minimum of 4 months 
of POM/LoDEX therapy and 
then reassess VTE risk. Consider switch 
to aspirin prophylaxis, continuously if risk 
factors no longer present
Assess VTE risk
(Risk factors: history of VTE, immobilisation, erythropoietin use)
Figure 4. Recommendations for determining appropriate thrombosis prophylaxis in patients with RRMM treated with POM/LoDEX. LMWH,
low-molecular-weight heparin; POM/LoDEX, pomalidomide plus low-dose dexamethasone; VTE, venous thromboembolism.
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discontinued in the rare but severe cases of generalised
exfoliative, ulcerative or bullous dermatitis.
Expert panel opinion
 Follow the recommended dose modiﬁcation scheme for other
pomalidomide-related adverse events (Figure 5)
IMPACT ON QUALITY OF LIFE
In MM-003, quality-of-life scores for Global Health Status and
Physical Functioning worsened signiﬁcantly by cycle 2 in patients
treated with high-dose dexamethasone.87 In comparison,
treatment with pomalidomide plus low-dose dexamethasone
signiﬁcantly prolonged the time to worsening of Global Health
Status and Physical Functioning scores. In addition, fewer patients
treated with pomalidomide plus low-dose dexamethasone
experienced worsening in Fatigue scores, compared with those
treated with high-dose dexamethasone. These ﬁndings suggest
that, in terms of overall quality of life, the improved antimyeloma
efﬁcacy of pomalidomide plus low-dose dexamethasone may
outweigh the negative impact of treatment-related adverse events
compared with high-dose dexamethasone.
USE IN SPECIAL POPULATIONS
Patients with renal impairment
Lenalidomide is mainly eliminated unchanged via the kidneys,
and renal impairment has been shown to reduce clearance of
lenalidomide. As a result, lenalidomide dose adjustments are
needed in patients with renal impairment to avoid excessive and
potentially toxic levels of the drug.3,88 In contrast, pomalidomide
is metabolised extensively before excretion; only 2% of
pomalidomide is excreted unchanged in the urine, compared
with 82% of lenalidomide.76 Compared with lenalidomide,
pomalidomide also has a slower rate of absorption and a longer
elimination phase in healthy volunteers and in patients with MM
(Table 1). It is therefore hypothesised that renal function will not
have a major effect on drug exposure.89
The available clinical data support the efﬁcacy and safety of
pomalidomide plus low-dose dexamethasone in patients with
creatinine clearance X45ml/min using the standard starting
doses. In a subanalysis of data from MM-002 in which patients
were classiﬁed according to creatinine clearance, the safety and
efﬁcacy of pomalidomide plus low-dose dexamethasone appeared
similar irrespective of the degree of renal function.52,90
A preplanned renal assessment in MM-003 showed that
treatment with pomalidomide plus low-dose dexamethasone
signiﬁcantly extended PFS and OS compared with high-dose
dexamethasone in patients with or without moderate renal
impairment.91,92 However, these results should be interpreted
Event Pomalidomide dose modification
Grade 3 rash (severe, generalised 
erythroderma or macular, papular or 
vesicular eruption; desquamation 
covering ≥50% body surface area)
• Hold dose
• If rash resolves to grade ≤1, 
 decrease by 1 dose level 
 at next cycle
Grade 4 rash (generalised exfoliative, 
ulcerative or bullous dermatitis) 
or rash with blistering
• Discontinue pomalidomide
Grade 3 peripheral sensory neuropathy 
(sensory alteration or paraesthesia 
interfering with activities of daily living)
• Hold dose
• If neuropathy resolves to grade ≤1, 
 decrease by 1 dose level at next cycle
Grade 4 peripheral sensory neuropathy 
(disabling)
• Discontinue pomalidomide
Grade ≥3 constipation (symptoms 
interfering with activities of daily living; 
obstipation with manual evacuation 
indicated; or life-threatening consequences)
• Hold dose and initiate bowel regimen
• If constipation resolves to grade ≤2, 
 decrease by 1 dose level at next cycle
Other pomalidomide-related grade 
≥3 events
• Hold dose
• If event resolves to grade ≤2, 
 decrease by 1 dose level at next cycle
Pomalidomide dose levels: 4 mg → 3 mg → 2 mg → 1 mg → discontinuation
Figure 5. Recommended pomalidomide dose modifications for other nonhaematological adverse events.65,66
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with caution because the number of patients in each subgroup
was small, and patients with severe renal impairment (serum
creatinine43mg/dl in MM-002 and creatinine clearanceo45ml/
min in MM-003) were excluded from these studies.16,52,90 An
ongoing phase I study (MM-008) will help determine the optimal
dose of pomalidomide when given with low-dose dexamethasone
in patients with severe renal impairment (creatinine clearance
o30ml/min).89,93 Preliminary data from this study indicate that
pomalidomide plus low-dose dexamethasone is well tolerated,
and dose escalation continues. A larger, phase IV study (MM-013)
has been initiated in Europe to assess the safety and efﬁcacy of
pomalidomide plus low-dose dexamethasone in patients with
RRMM and moderate-to-severe renal impairment, including those
undergoing dialysis.
Expert panel opinion
 It is not necessary to adjust the dose of pomalidomide 4mg in
patients with mild-to-moderate renal impairment (creatinine clear-
ance X45ml/min)
 More data are needed on the use of pomalidomide plus low-dose
dexamethasone in patients with severe renal impairment
 Monitor closely for adverse events in patients with renal impairment
who are being treated with pomalidomide
Patients with unfavourable cytogenetics
In MM-002, pomalidomide plus low-dose dexamethasone showed
promising activity in the subset of patients with unfavourable
cytogenetics (del[17p] and/or t[4;14])94 and, in MM-003, treatment
with pomalidomide plus low-dose dexamethasone resulted in
signiﬁcantly better PFS and OS than with high-dose
dexamethasone, regardless of cytogenetic risk group.95
However, in IFM 2009-02, the presence of high-risk cytogenetics
(del[17p] and/or t[4;14]) negatively affected outcomes: the 1-year
OS rate in this cohort was 27% compared with 67% in patients
with no cytogenetic abnormalities.15 In a phase II conﬁrmatory
trial (IFM 2010-02) evaluating pomalidomide plus low-dose
dexamethasone in 50 patients with del(17p) and/or t(4;14), the
median TTP and OS were 3 and 12 months, respectively.96
Notably, patients with del(17p) appeared to beneﬁt more from
treatment with pomalidomide plus low-dose dexamethasone than
did those with t(4;14): the median TTP was 8 months vs 3 months
and median OS was not reached vs 9 months, respectively.
In another phase II study of 71 patients with high-risk disease,
deﬁned by gene-expression proﬁling (GEP70 or GEP80 signatures),
increased lactate dehydrogenase levels or metaphase cytogenetic
abnormalities, pomalidomide-based therapy had good
antimyeloma activity: 28% of patients had a partial response or
better; 82% had stable disease or better; and the 1-year PFS and
OS rates were 13% and 63%, respectively.97 These data need to be
interpreted with caution because of the relatively small number of
patients, and additional data are needed.
Expert panel opinion
 Although more data are needed on the efﬁcacy of pomalidomide plus
low-dose dexamethasone in patients with unfavourable cytogenetics,
this regimen is an appropriate option
Patients with advanced age
In IFM 2009-02, response to pomalidomide plus low-dose
dexamethasone was not affected by age, and its safety proﬁle in
the subset of patients aged X65 years (n¼ 26) was acceptable.15
Survival outcomes were generally less favourable in older patients
in both arms, compared with younger patients, as is usually the
case in myeloma patients. Similarly, in MM-002, response to
pomalidomide plus low-dose dexamethasone was not affected by
age, and the safety proﬁle was generally similar in patients aged
p65 and 465 years.98,99 The incidence of pneumonia, however,
was increased in older patients (29% vs 16%), underscoring
the need for appropriate antibiotic prophylaxis in patients
at risk of pneumonia. In MM-003, a subanalysis indicated that
Dexamethasone 
dose adjusted for agea
Antibiotic prophylaxisd
G-CSF prophylaxisb
Thromboprophylaxise
Pomalidomide 4 mg/dayc
Low-dose dexamethasone weekly
Figure 6. Considerations for initiation of pomalidomide plus low-dose dexamethasone therapy. G-CSF, granulocyte colony-stimulating factor;
VTE, venous thromboembolism. aPatients475 years of age should receive dexamethasone 20mg weekly; younger patients should receive a
dose of 40mg weekly. bG-CSF use may be considered for the first three cycles to prevent neutropenia. cThe recommended starting dose of
pomalidomide is 4mg/day, regardless of the presence of comorbidity. dAntibiotic prophylaxis may be considered for the first three cycles of
therapy to reduce the risk of infection. eThromboprophylaxis should be considered for all patients receiving pomalidomide plus low-dose
dexamethasone to reduce the risk of VTE.
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the efﬁcacy and safety proﬁles of pomalidomide plus low-dose
dexamethasone were not affected by age (o65 vsX65 years).16 It
should be noted that in MM-002 and MM-003, a reduced dose of
dexamethasone (20mg weekly) was used in patients475 years of
age14,16 as is generally recommended for older patients with
MM.75 Future trials should assess the use of alternative steroids
(that is, prednisone) in elderly myeloma patients treated with
pomalidomide.
Expert panel opinion
 No dose adjustments of pomalidomide according to age are required
 Reduce the dose of dexamethasone to 20mg weekly in patients475
years of age
CONCLUSIONS AND FUTURE DIRECTIONS
The pomalidomide plus low-dose dexamethasone regimen repre-
sents an important new treatment option for patients with RRMM
refractory to lenalidomide and bortezomib. The improvements in
PFS and OS indicate that pomalidomide plus low-dose dexametha-
sone has the potential to change the course of the disease,16 and
corresponding improvements in patient condition16,87 are helping to
expand therapeutic options after treatment with pomalidomide plus
low-dose dexamethasone. These encouraging results highlight the
importance of the appropriate use of pomalidomide, including
adequate dose and prophylaxis for neutropenia, infection and VTE
(Figure 6). Addressing these factors can help haematologists and
oncologists maximise efﬁcacy and minimise safety risks during
pomalidomide treatment.
The optimal sequence and choice of agents in RRMM has not
yet been established, and treatment decisions are left to the
treating physician based on the needs of the individual patient
and the availability of drugs. For patients who have exhausted
lenalidomide- and bortezomib-based therapies, pomalidomide
plus low-dose dexamethasone is an effective treatment option.
Evidence suggests that pomalidomide is equally effective in
patients whose last therapy was lenalidomide or bortezomib.16
Pomalidomide plus low-dose dexamethasone could be an option
for second-line therapy in patients with disease that failed ﬁrst-line
therapies with a combination of proteasome inhibitors and
immunomodulatory drugs such as lenalidomide, bortezomib and
dexamethasone.
More data are needed on the use of pomalidomide plus low-
dose dexamethasone in certain subpopulations of patients with
RRMM, including those with renal impairment or unfavourable
cytogenetic features. The ongoing MM-008 and MM-013 studies
will provide much-needed data on the use of pomalidomide in
patients with renal impairment (including dialysis patients) that
will help develop an evidence-based dose-modiﬁcation strategy
for pomalidomide in this setting.89,93 Ongoing studies, IFM 2010-
02 (NCT01745640) and MM-010 (NCT01712789), will provide
further data on the impact of cytogenetic features and may help
identify markers of response. Currently, data on the role of
cereblon as a biomarker are not strong enough to recommend its
use in clinical practice.
Novel pomalidomide-based regimens continue to be explored.
Preliminary evidence from phase I/II trials indicates that
the combination of pomalidomide, cyclophosphamide and
prednisone is feasible in RRMM100 as is the combination
of clarithromycin, pomalidomide and dexamethasone101 and
pegylated liposomal doxorubicin, pomalidomide and dexame-
thasone.102 Trials evaluating proteasome inhibitors in combination
with pomalidomide and dexamethasone are also underway.103–104
These studies will help further deﬁne the role of pomalidomide in
the management of RRMM.
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